Navigation Links
Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Date:2/12/2008

le by going to the Investor Relations section of the Schering-Plough corporate Web site, http://www.schering-plough.com, and clicking on the "Presentations/Webcasts" link. A replay of the webcast will be available starting on Feb. 12 through 5 p.m. on March 11.

DISCLOSURE NOTICE: The information in this press release, the comments of Schering-Plough officers during the earnings teleconference/webcast on Feb. 12, 2008, beginning at 8 a.m. (EST), and other written reports and oral statements made from time to time by the company may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements do not relate strictly to historical or current facts and are based on current expectations or forecasts of future events. You can identify these forward-looking statements by their use of words such as "anticipate," "believe," "could," "estimate," "expect," "forecast," "project," "intend," "plan," "potential," "will," and other similar words and terms. In particular, forward-looking statements include statements relating to the company's plans; its strategies; its progress under the Action Agenda and anticipated timing regarding future performance of the Action Agenda; business prospects; anticipated growth; timing and conditions of regulatory approvals and expected synergies related to the Organon BioSciences acquisition; prospective products or product approvals; trends in performance; anticipated timing of clinical trials and its impact on R&D spending; anticipated exclusivity periods; actions to enhance clinical, R&D, manufacturing and post-marketing systems; and the potential of certain products including VYTORIN and ZETIA and trending in the cholesterol market. Actual results may vary materially from the company's forward-looking statements, and there are no guarantees about the performance of Schering- Plough stock or Schering-Pl
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Schering-Plough and OraSure Technologies Sign International Collaboration for Rapid Point-of-Care Oral Hepatitis C Test
2. Schering-Plough Announces Organizational Changes at Schering-Plough Research Institute
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Schering-Plough Announces Sugammadex New Drug Application Filed in Japan
5. Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA
6. Schering-Plough to Webcast Presentation at Morgan Stanley Pharmaceutical CEOs Unplugged Conference
7. Schering-Plough Schedules Conference Call and Webcast for 2007 Fourth Quarter, Full-Year Financial Result
8. Schering-Plough Wins Three of Scrips Top Pharma Industry Awards
9. Schering-Plough Completes Acquisition of Organon BioSciences
10. Schering-Plough Receives Approval from European Commission for Planned Acquisition of Organon BioSciences N.V.
11. Schering-Plough to Webcast Presentation at Merrill Lynch Global Pharmaceutical, Biotech & Medtech Conference

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...stCall/ -- Dendreon Corporation (Nasdaq: DNDN ) t...tration (FDA) provided written acknowledgement tha...ion (BLA) for PROVENGE® (sipuleucel-T) is a c...tion Drug User Fee Act (PDUFA) date of May 1, 2010...ded BLA. Dendreon is seeking licensure for PROVEN...
(Date:11/20/2009)...ently announced that Dr. Dominique Hebrault will p...Analytical Technology (PAT) in Green Chemistry and... (PRWEB) November 20, 2009 ...nology (PAT) in Green Chemistry and Green Engineer...hnology (PAT) case studies will be presented on ho...
(Date:11/19/2009)...9 Spherix Incorporated (... diabetes therapy, and a provider of technical and...t, biotechnology and pharmaceutical companies, ann...3 million registered direct placement to instituti...tock and warrants to purchase up to 1,104,348 addi...
(Date:11/19/2009)...Aegera Therapeutics Inc. announced today the dosin...udy of AEG35156, a targeted antisense therapeutic ...ications. ,, The study, entitled "An Open-Label...r of Apoptosis (XIAP) Antisense AEG35156 Given in ...in in AML Following Failure of a Single Standard D...
Breaking Biology Technology:Dendreon Receives FDA Acknowledgement of Complete Response 2Dendreon Receives FDA Acknowledgement of Complete Response 3Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2
...gae is a livid green giveaway of nutrient pollutio...at action in tiny particles that would turn differ...spoilage or signs of poor health in the blood. , ... have tapped the working parts of cells to clear a...eat, which signifies a new approach to technology ...
... N-Viro International Corporation,(OTC Bulletin B...ing company,that owns patented technologies to con...ative fuel products, announces its renewable biofu...elines set forth by the U.S.,Environmental Protect...gy,source that may be utilized in commercial power...
...vania and REHOVOT Israel, January 16, Rosetta Geno...y unveiled initial data relating to the company,s,...creen(TM) colon, which is,based on a simple blood ...e,company,s scientists and collaborators have iden...e potential to accurately differentiate colorectal...
Other Biology Technology:Researchers: Molecular forklifts overcome obstacle to 'smart dust' 2Researchers: Molecular forklifts overcome obstacle to 'smart dust' 3N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency 2N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency 3N-Viro Fuel Technology Receives Alternative Energy Status From the U.S. Environmental Protection Agency 4Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum 2Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum 3Rosetta Genomics and Collaborators Unveil Colon Cancer Screening Diagnostic; Identified Candidate MicroRNA Biomarkers in Serum 4
(Date:11/20/2009)...ass from the production of flax shives, and genera...ant related to those which engulf fields in spring... suggested by two studies carried out by Spanish a... Renewable and Sustainable Energy Reviews . , "Th...of view, the production of bioethanol from two, as...
(Date:11/19/2009)...ghly 15,000 years ago, at the end of the last ice ...als including such iconic creatures as mammoths, ... beavers began their precipitous slide to extinct...ing a land whose diversity of large animals equale...ains then or now, an entirely novel ecosystem emer...
(Date:11/19/2009)...ng Harbor, NY A four-year, multi-institutional ef... (CSHL) scientists culminated today in publication...ience revealing in unprecedented detail the DNA s...it is commonly called by North American consumers,...he most valuable agricultural crop grown in the Un...
Breaking Biology News(10 mins):Flax and yellow flowers can produce bioethanol 2After mastodons and mammoths, a transformed landscape 2After mastodons and mammoths, a transformed landscape 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 2Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 3Reference genome of maize, most important US crop, is published by team co-led by CSHL scientists 4Florida Hospital Cardiovascular Institute Completes House Wide Implementation of the LifeSync 28R 29 Wireless ECG System 47699 1Florida Hospital Cardiovascular Institute Completes House Wide Implementation of the LifeSync 28R 29 Wireless ECG System 47699 2Florida Hospital Cardiovascular Institute Completes House Wide Implementation of the LifeSync 28R 29 Wireless ECG System 47699 3Understand ARRA Spending Allocations with HIMSS Analytics 26amp 3B 238482 3B Market Intelligence 47698 1Understand ARRA Spending Allocations with HIMSS Analytics 26amp 3B 238482 3B Market Intelligence 47698 2Understand ARRA Spending Allocations with HIMSS Analytics 26amp 3B 238482 3B Market Intelligence 47698 3Dr Erika Says Newsweek 26apos 3Bs Attack on Oprah Ignores the Many Benefits of Her Health Care Advocacy 47696 1Dr Erika Says Newsweek 26apos 3Bs Attack on Oprah Ignores the Many Benefits of Her Health Care Advocacy 47696 2
...anotechnology, researchers are continually on the ... and discovery to scales much smaller than the tin... at Arizona State University, researchers are usin...g at this scale holds great potential for advancin...thought of as the molecule of life, is an ideal bu...
...at Cold Spring Harbor Laboratory have for the firs...ary glands of mice to grow even after birth. They ...these cells are distinct from those that fuel the ...s suggest a novel way that the hormone-secreting g... traumatic stress or to normal life changes like p...
...inal pigment epithelial (RPE) cells attached to ti...in can improve the symptoms of patients with moder...niversity Medical Center neurosurgeon Dr. Roy A. E...nta found the therapy Spheramine was well-tolerate...nian symptoms (tremor, rigidity, slowness of movem...
Other Biology News:Scientists make chemical cousin of DNA for use as new nanotechnology building block 2Scientists make chemical cousin of DNA for use as new nanotechnology building block 3Scientists find stem cells for the first time in the pituitary 2Scientists find stem cells for the first time in the pituitary 3Cell-based therapy shows promise in patients with Parkinson's disease 2Cell-based therapy shows promise in patients with Parkinson's disease 3
Mouse Anti-Human Actopaxin, phospho (Ser8) Monoclonal Antibody, Unconjugated, Clone J160-366 from BD Biosciences Pharmingen
Anti-gp64 Antibody, Unconjugated from Novagen
Rabbit Anti-b-Catenin, phospho (Ser675) Antibody, Unconjugated from Spring Bioscience
Rabbit Anti-Human Naked1 Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Biology Products: